PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Friday, June 14, 2013

AllTrials - the countdown begins

Posted on 2:19 PM by Unknown

Drug companies have a year to publish their data, or we’ll do it for them

Cqghbjfx-1371129879

As a doctor it’s my job to prescribe lotions and potions. To do so, I read information about drug trials in books and medical journals to keep me up to speed on the latest drugs, dangers and side effects.

But what if what I read is part of an elaborate marketing strategy by a drug company to use me to get to you?

This happens all the time. So much so that the saturation of scientific literature with commercial messages has come to the point where some of those of us who work full time in this area don’t trust the literature anymore. I can read something about a drug and find that the majority of the data about it – for example as I arguedin a recent article on Tamiflu – is missing.

This is not because the work hasn’t been done, but because it has been deliberately hidden. What has been published might have important discrepancies with what probably really happened during a clinical trial into the drug. We just don’t know.

It’s a story that involves everyone: scientists, pharmaceutical sponsors, editors of biomedical journals and the media. Ultimately it is you who suffers.

At school, if you made a mistake the teacher would ask you to explain it and get you to correct it in your exercise book. The same should go for unpublished and misreported trials. They should be published and formally corrected to ensure doctors and patients can rely on complete and accurate information about the treatments we use.

In the public domain we have hundreds of highly detailed regulatory reports of trials which were never published (invisible) or distorted in the way the results were presented. Some were even ghost written and we also know by whom and for how much money.

A year to publish and correct

There is now a proposal, backed by the British Medical Journal(BMJ) and PLOS Medicine, to ask drug companies to publish and correct all data – including on medicines already in circulation – within the next year. Otherwise independent scientists will begin doing it themselves.

Volunteer researchers – currently being signed up – will be able to pick an invisible or distorted trial, write to the drug’s sponsor and ask them to make it visible or correct the record – and drug companies will be given a year to do it.

If the company doesn’t respond within 30 days or turns the offer down, friendly journals will publish the paper and a longer one for the regulators.

This way we can have several published versions of the same trial, with different interpretations and different data sets. There will be more free debate based on the data and no-one will have a monopoly control. Everything will be out in the open and will potentially be good for your health.

You may think that multiple versions of the same trial or many public letters and correspondence may cause confusion. But this controlled release of information is precisely what has brought us to this situation.

In the Middle Ages scientists were kept under control by physical threats, today control is exerted on what information we’re able to see. An open society needs an open debate – with all the data available.

https://theconversation.com/drug-companies-have-a-year-to-publish-their-data-or-well-do-it-for-them-15184

Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ►  July (104)
    • ▼  June (81)
      • China detains GlaxoSmithKline staff for fraud: rep...
      • Get in the sack
      • Tamiflu saga continues - NYT. By Katie Thomas
      • Gouging the patient - 1boringoldman explains
      • Deen dumped
      • FDA shuts down 1,677 online pharmacies
      • Treasure Ireland contd.
      • SEC charges medical imaging firm CEO for lying on ...
      • Sleepy Seroquel
      • Federal lawmakers urge FDA to change rules to allo...
      • #UMNProud
      • Nemeroff in London - let's see the slides
      • Pfizer still on the asbestos hook
      • Meet the new Mr NICE Guy
      • Of the 86 drugs in the industry's diabetes pipelin...
      • Sometimes it is best to do nothing. A "must read "...
      • Evidence Based Medicine - Why we can’t trust clini...
      • Pharmaceutical scandal: 'You pay us £300. However,...
      • SCANDAL
      • Who's who at Quantum Pharmaceuticals?
      • Busted! No Solace for Quantum
      • Saying no to chemotherapy by Des Spence - BMJ
      • For you - special price!
      • Zalcrap contd.
      • Your puny western ads don't work on our Russian wo...
      • UK plans to cut some drug prices by up to 20 per cent
      • A Fistful of Dollars - The Cephalon off label way
      • A Smoking Pillbox: Evidence that Sgt. Bales May Ha...
      • Nine pharmas fined by EU
      • Jagemeister PR - you're doing it wrong
      • For AZ's Onglyza SAVOUR is not a saviour
      • EU fines Lundbeck for paying off pharma rivals
      • Young Law Group Announces Initiative Prosecuting A...
      • FDA Probes Deaths Linked to Long-Acting Zyprexa
      • A holy mess
      • J&J buy Aragon
      • Introducing polypill.com - medication for the mass...
      • FT - Professor turns to internet to distribute pol...
      • Shire Pharmaceuticals Ltd and Roche Products Limit...
      • NIH Censoring Expert to Prevent Criticism of Ethic...
      • Merck announces it will slash jobs at research lab...
      • AllTrials - the countdown begins
      • Experts Propose Restoring Invisible And Abandoned ...
      • The Painful Politics of Painkillers Opioids are de...
      • GSK - Little Trouble in Big China
      • No dishonour in depression
      • Healing the Overwhelmed Physician - by Jerry Avorn
      • GlaxoSmithKline Fires China R&D Boss for 'Misrepre...
      • Charles Nemeroff - Honoured in Britain, the US psy...
      • How Big Pharma Drives Up Medicare Spending Without...
      • Walgreens pays record $80 million settlement for i...
      • Has pancreatic damage from glucagon suppressing di...
      • Austerity is bull!
      • Obama administration reverses course on Plan B pill
      • Corporate Whistle Blower Center Now Urges Pharmace...
      • Endo Implodes
      • Introducing OTC Toolbox
      • Pearl bought
      • Johnson & Johnson seeks home court advantage in Ty...
      • The geography of antidepressant, antipsychotic, an...
      • One to watch - Dispatches, Channel 4, Monday June ...
      • How much is your doctor making from Big Pharma?
      • Not just Bad - Ineffective Pharma!
      • Not just Bad - Filthy Pharma
      • Big data to sniff out drug marketing fraud
      • Dr Sidney Wolfe retires with a bang!
      • Kerching!
      • No-user, no cry
      • Nine pharma firms face EU fines over pay-for-delay...
      • Here for a good time or a long time?
      • Yet another J&J recall!
      • The Myth of the New
      • Keepy-uppy!
      • Meet the Doctor Big Pharma Can't Shut Up
      • In Memoriam: Barbara A. Brenner, 1951-2013
      • Pink Ribbons Inc. - watch the movie
      • Gouging 101 spotted by Dr Judy Stone
      • Summer Reading contd. Blood Medicine by Kathleen S...
      • Corporate fines are puny
      • "Brad Abbey" on Ben Goldacre
      • AllTrials contd. - D Day for comments - June 10th
    • ►  May (5)
Powered by Blogger.